DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Analyst Optimism | Discover why analysts set price targets ranging from $7.39 to $21.15, reflecting confidence in DBV's pipeline and market potential |
Financial Crossroads | Delve into DBV's financial position, including its $128 million cash reserves and potential $180 million warrant exercise, as it approaches critical milestones |
Market Opportunity | Explore the vast potential of the pediatric peanut allergy market, with projected peak sales exceeding $2 billion for Viaskin Peanut |
Peanut Allergy Pionee | DBV Technologies leads innovation in food allergy treatment with Viaskin Peanut, a non-invasive epicutaneous immunotherapy showing promise in clinical trials |
Metrics to compare | DBVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDBVTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.7x | −2.0x | −0.5x | |
PEG Ratio | −0.88 | 0.31 | 0.00 | |
Price / Book | 7.5x | 3.1x | 2.6x | |
Price / LTM Sales | 225.6x | 3.9x | 3.2x | |
Upside (Analyst Target) | 119.8% | 25.8% | 47.6% | |
Fair Value Upside | Unlock | 14.0% | 6.1% | Unlock |